Moonshots

Peter Diamandis × Salim Ismail × Dave Blundin × Alexander Wissner-Gross × Ben Lamm

Colossal is now worth over $10 billion with more than four spin-offs, while AI connects fragmented research and addresses 40–60% replication failure through standardized language.That data infrastructure may matter more than the model itself as comparative genomics spans thousands of genomes.Colossal has surpassed 300 edits at over 90% efficiency and is testing 1,000, with large-fragment DNA synthesis and a fully extrauterine mammalian birth within 24 months as catalysts amid ethical and regulatory constraints.

Peter Diamandis × Martine Rothblatt

United Therapeutics has four thymus shots on goal, including an FDA-approved xenothymus program and newly acquired Thymmune, making thymic replacement Rothblatt’s “most practical pathway” to LEV in the 2030s.Its xeno-kidney trial is mid-flight, facilities are slated for Rochester in August and Houston in October, and xeno-heart moved to Phase 3 after two patients survived 60 days without heart failure, with IVIVA trials starting in 2028.

Peter Diamandis × Emad Mostaque × Dave Blundin × Dr. Alexander Wissner-Gross

Anthropic’s confidential IPO could make frontier AI a public-market asset class; Polymarket assigns a 60% chance of valuation above $1.8 trillion.ChatGPT’s reported one billion monthly users make distribution central as falling intelligence costs intensify the race for each user’s coordinating assistant.Trump’s voluntary 30-day review and DNA-screening debate leave governance unresolved while robotics and longevity attract sovereign-scale capital.

Peter Diamandis × Ben Lamm

Colossal uses de-extinction as a proving ground for an AI-enabled synthetic-biology platform, growing to 260 scientists and a reported $10 billion valuation in four years.Spinouts such as Breaking and a UAE-backed animal biovault show how platform discoveries could become commercial and sovereign infrastructure businesses.Artificial wombs remain the scaling unlock but all three projects “don’t work yet,” leaving edit efficiency, cloning economics, regulation, and gene-drive containment as material milestones.

Ben Lamm × Salim Ismail × Peter Diamandis

Colossal’s dire-wolf launch is a platform proof: 20 edits, including 15 ancient variants, produced healthy animals expressing phenotypes driven by genes lost for 12,000 years.Its integrated software-biology stack, artificial-womb program, and prospective technology, nature-credit, and government-service businesses create multiple catalysts, while execution, governance, and taxonomy remain material risks.

Peter Diamandis × Mary Lou Jepsen

Openwater is building a software-defined “silicon hospital” that combines infrared light, ultrasound, electromagnetics, AI, and commodity chips to shrink multimillion-dollar medical systems toward $1,000 modules.Stroke triage is the clearest commercial wedge, but the FDA’s request for 10,000 additional patients could create a $400–$700 million validation bill; promising depression, cancer, and microclot results remain separated across small clinical studies and preclinical lab work.